The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
News & Analysis: Codexis
This favorite of institutional shareholders remains off the radars of most retail investors.
Despite nearly meeting its full-year 2019 product revenue guidance after just three quarters, the company didn't raise guidance. What does that mean?
CDXS earnings call for the period ending September 30, 2019.
Your money can buy more shares of these promising companies thanks to an affordable stock price.
The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?
CDXS earnings call for the period ending June 30, 2019.
These low-priced shares should be on your radar.
The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.